Overview
Corporate ProfileOur success is supported by a proven strategy of marketing high-growth, innovative products, building our marketing and distribution channels, and investing in unique compounds that may change the course of disease. Our strategy balances the risk in our business and further distinguishes Cephalon from the majority of its peers. Featured Presentation |
|
|
| Date | Title | | | 10/13/11 | Cephalon Announces Enrollment In the Risk Evaluation and Mitigation Strategy Program for FENTORA and ACTIQ| FRAZER, Pa., October 13, 2011 – Cephalon, Inc. (Nasdaq: CEPH) announced that healthcare professionals, pharmacies, and distributors who prescribe and dispense FENTORA® (fentanyl buccal tablet) [C-II] and ACTIQ® (oral transmucosal fentanyl citrate) [C-II] can enroll in the recently approved Risk Evaluation and Mitigation Strategy (REMS) program. The primary method for prescriber and pharmacy enrollment is online at www.actiqandfentorarems.com. A call center is available to provide add... |
|  | | 08/22/11 | Cephalon Gives Notice of Anticipated Fundamental Change to Holders of Its 2.50% Convertible Senior Subordinated Notes due 2014 and 2.00% Convertible Senior Subordinated Notes due 2015| FRAZER, Pa., Aug. 22, 2011 /PRNewswire via COMTEX/ -- Cephalon, Inc. (Nasdaq: CEPH) today provided notice to holders of its 2.50 percent Convertible Senior Subordinated Notes due 2014 (the "2014 Notes") and 2.00 percent Convertible Senior Subordinated Notes due 2015 (the "2015 Notes") in respect of the Merger (as defined below) of the Company with a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., an Israeli corporation ("Parent"), the consummation of which will constitute a Funda... |
| | | 08/02/11 | Cephalon Reported Financial Results for the Second Quarter of 2011|
Sales For The Period Were $730 Million
Basic Income Per Common Share Increased 31 Percent
FRAZER, Pa., Aug. 2, 2011 /PRNewswire via COMTEX/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported second quarter 2011 net sales of $730.1 million, a 2 percent increase compared to net sales of $712.4 million for the second quarter of 2010. Basic income per common share for the period was $1.54 compared to $1.18 for the second quarter of 2010. Excluding amortization expense and certain other items, adjus... |
| | | 07/21/11 | Cephalon Receives FDA Approval for Risk Evaluation and Mitigation Strategy for FENTORA and ACTIQ| FRAZER, Pa., July 21, 2011 /PRNewswire via COMTEX/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that the U.S. Food and Drug Administration (FDA) approved the Risk Evaluation and Mitigation Strategy (REMS) for FENTORA® (fentanyl buccal tablet) [C-II] and ACTIQ® (oral transmucosal fentanyl citrate) [C-II]. Both products are indicated for the management of breakthrough pain in opioid-tolerant patients with cancer. Under this REMS, pharmacies and healthcare professionals who prescribe FENTORA an... |
| |
|
|
| There are currently no events scheduled. |
Print Page | 
Email Page |